Biovail tramadol ODT approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biovail will select a trade name for its orally disintegrating tramadol (formerly Ralivia FlashDose) once it finds a marketing partner for the opioid analgesic, cleared May 5 for moderate to moderately severe pain in adults. Late-stage discussions with potential partners are underway, the firm said. Biovail also has an extended-release tramadol formulation (formerly Ralivia ER) pending, which has been "approvable" since October 2004. The firm expects to submit additional data in late 2005/early 2006 (1Pharmaceutical Approvals Monthly April 2005, In Brief)...
You may also be interested in...
Biovail tramadol ER needs more data
Biovail expects to submit data from a new clinical trial of its orally disintegrating extended-release tramadol product in late 2005/early 2006, the firm said March 30. The announcement follows initial feedback from FDA regarding Biovail's March 2005 complete response to an October 2004 "approvable" letter for the opioid analgesic. "Upon preliminary review, [FDA said] it is of the opinion that additional clinical trial data will be required," the company said. Biovail maintains that its 505(b)(2) NDA is sufficient and plans to meet with FDA to discuss its options. The setback could allow Labopharm to file its extended-release tramadol ahead of Biovail; the Canadian firm previously projected a second-half 2005 filing (1Pharmaceutical Approvals Monthly October 2004, p. 7)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.